Triptorelin is a gonadotropin releasing hormone (GnRH) agonist, it is an inhibitor of synthesis of testosterone (in men) and estrogen (in women), which is used for the treatment of central precocious puberty (CPP) and advanced prostate cancer. According to the National Center for Biotechnology Information (NCBI): 2018, triptorelin is found to be associated with a very low rate of elevations of transient serum enzyme during its therapy for various conditions like central precocious puberty (CPP) and prostate cancer.
Market Dynamics
According to Optum, a provider of integrated health services, has put forth some of the guidelines for the administration of Triptodur (triptorelin). As per the National Health Service, the recommended dosage of Triptodur is 22.5 mg, and it is administered as a single intramuscular injection once every 24 weeks. The following are the guidelines which has to be followed while administering the drug:
- Triptodur must be administered only under the supervision of a physician
- Triptodur treatment should be discontinued at the appropriate age i.e. the treatment is stopped at the onset of puberty and it is recommended by the physician
- Once Triptodur has been administered, the response to Triptodur should always be monitored by monitoring the following factors: luteinizing hormone (LH)levels after a Gonadotropin-releasing hormone (GnRH) or GnRH agonist stimulation test, basal LH, or serum concentration of sex steroid levels beginning 1 to 2 months following initiation of therapy, during therapy as necessary to confirm maintenance of efficacy and with each subsequent dose.
- After the administration of the drug Triptodur, the patient’s height should be measured every 3 to 6 months and bone age should be monitored periodically
Market players are indulged in inorganic activities such as acquisition, in order to distribute the drug triptorelin in the U.S., this is expected to drive the growth of the U.S. triptorelin market over the forecast period. For instance, in January 2016, Debiopharm International SA (Debiopharm), part of Debiopharm Group, a Swiss-based global biopharmaceutical company, and Arbor Pharmaceuticals, LCC (Arbor), a U.S.-based specialty pharmaceutical company, entered into a distribution agreement for the commercialization and promotion of triptorelin 22.5 mg in the U.S. for central precocious puberty (CPP). Under the terms of the agreement, Arbor Pharmaceuticals, LCC, acquired exclusive commercial rights for triptorelin 22.5 mg in the U.S., for the CPP indication. The product was exported from Debiopharm Research and Manufacturing SA to Arbor and was made available primarily to pediatricians and pediatric endocrinologists.
Key features of the study:
- This report provides an in-depth analysis of the S. triptorelin market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the S. triptorelin market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Aero Medical Ambulance Service, Aero-Dienst GmbH, Airlec Air Espace, U.S.an Air Ambulance, Flightserve International, IAS Medical, Medical Air Service, Quick Air Jet Charter GmbH, Babcock Scandinavian Air Ambulance, Capital Air Ambulance
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The S. triptorelin market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the S. triptorelin market
Detailed Segmentation:
- U.S. Triptorelin Market, By Product Type:
- Triptorelin Pamoate
- Triptorelin Acetate
- Triptorelin Embonate
- U.S. Triptorelin Market, By Application:
- Prostate Cancer
- Radical Prostatectomy
- Endometriosis
- Salivary Gland Cancer
- Central Precocious Puberty
- U.S. Triptorelin Market, By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- International
- Company Profiles
- Ipsen USA*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Bachem Americas, Inc.
- Ferring Pharmaceuticals USA
- Reddy’s Laboratories Ltd
- Teva Pharmaceutical Industries Ltd.
- Arbor Pharmaceuticals, LLC
- Watson Laboratories, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
